Rachel Schiff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rachel Schiff has a total of 487 co-authors. Here are the top co-authors by number of shared publications:
- Carmine De Angelis
Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
138 shared publications - Susan Galloway Hilsenbeck
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas
136 shared publications - Matthew Philip Goetz
Department of Oncology, Mayo Clinic, Rochester, USA
103 shared publications - Tao Wang
Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, USA
67 shared publications - Mothaffar F. Rimawi
Baylor College of Medicine, Houston, TX, USA
66 shared publications - Matthew James Ellis
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
65 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Figure S10. Kaplan-Meier plots of individual EnR-CIPs analyzed in METABRIC and kmPlotter databases.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Figure S10. Kaplan-Meier plots of individual EnR-CIPs analyzed in METABRIC and kmPlotter databases.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Figure S1. Relative abundance of sphingolipids in multiple ET-resistant cell lines.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Figure S1. Relative abundance of sphingolipids in multiple ET-resistant cell lines.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Despite the success of endocrine therapy (ET) in treating hormone receptor–positive breast cancer, a significant proportion of patients relapse during or after treatment, making ET resistance a major clinical challenge. Previously, we have shown that ET-resistant breast cancer cells exhibit reduced ceramide levels and an increased sensitivity to ceramide-induced cell death. In this study, we demonstrate that ceramides induce a distinct transcriptional reprogramming in ET-resistant cells, characterized by upregulation of endoplasmic reticulum stress (EnRS) pathways. Ceramide-induced EnRS is PERK-dependent and functionally linked to cell death in multiple models of ET resistance. Using a photoactivatable ceramide probe, we identify TRAM1 as a functionally important ceramide-interacting protein (CIP) in ET-resistant cells that correlates with worse relapse-free survival and a more aggressive breast cancer phenotype in patients with luminal breast cancer. Additionally, knockdown of TRAM1 phenocopies ceramide action in ET resistance, thereby suggesting its role in mediating ceramide-induced lethal actions in ET resistance. Together, our findings reveal that ET-resistant breast cancer cells are highly sensitive to PERK-mediated EnRS relative to ET-sensitive cells. Ceramides, likely via interactions with CIPs such as TRAM1, lead to PERK activation and consequential cell death in the ET-resistant breast cancer models. This sensitivity to ceramide-induced EnRS and cell death is a vulnerability that could be taken advantage of to treat ET-resistant breast cancer. Implications:This study elucidates the functional relevance of ceramide depletion in ET-resistant breast cancer cells.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Despite the success of endocrine therapy (ET) in treating hormone receptor–positive breast cancer, a significant proportion of patients relapse during or after treatment, making ET resistance a major clinical challenge. Previously, we have shown that ET-resistant breast cancer cells exhibit reduced ceramide levels and an increased sensitivity to ceramide-induced cell death. In this study, we demonstrate that ceramides induce a distinct transcriptional reprogramming in ET-resistant cells, characterized by upregulation of endoplasmic reticulum stress (EnRS) pathways. Ceramide-induced EnRS is PERK-dependent and functionally linked to cell death in multiple models of ET resistance. Using a photoactivatable ceramide probe, we identify TRAM1 as a functionally important ceramide-interacting protein (CIP) in ET-resistant cells that correlates with worse relapse-free survival and a more aggressive breast cancer phenotype in patients with luminal breast cancer. Additionally, knockdown of TRAM1 phenocopies ceramide action in ET resistance, thereby suggesting its role in mediating ceramide-induced lethal actions in ET resistance. Together, our findings reveal that ET-resistant breast cancer cells are highly sensitive to PERK-mediated EnRS relative to ET-sensitive cells. Ceramides, likely via interactions with CIPs such as TRAM1, lead to PERK activation and consequential cell death in the ET-resistant breast cancer models. This sensitivity to ceramide-induced EnRS and cell death is a vulnerability that could be taken advantage of to treat ET-resistant breast cancer. Implications:This study elucidates the functional relevance of ceramide depletion in ET-resistant breast cancer cells.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Supplementary Table S10. Kaplan-Meier plots of individual EnR-CIPs analyzed in METABRIC and kmPlotter databases.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Supplementary Table S10. Kaplan-Meier plots of individual EnR-CIPs analyzed in METABRIC and kmPlotter databases.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Figure S8. Validation of ceramide actions in PDxO models.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Figure S8. Validation of ceramide actions in PDxO models.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Figure S3. Validation of RNA-seq by RT-qPCR.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Figure S3. Validation of RNA-seq by RT-qPCR.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Supplementary Table S6 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Supplementary Table S6 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Supplementary Table S5. Common upregulated and downregulated genes
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Supplementary Table S5. Common upregulated and downregulated genes
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Figure S2. Intracellular delivery of C8-ceramide.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Figure S2. Intracellular delivery of C8-ceramide.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Table S1. Ingenuity Canonical Pathways
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer
Table S1. Ingenuity Canonical Pathways